Mayo clinic shows infliximab ‘well tolerated’

Short and long-term infliximab therapy for Crohn’s disease (CD) is generally well tolerated by patients, data from the Mayo Clinic in Rochester, Minnesota, USA, reveal. Reporting in the journal Gastroenterology, however, William Sandborn and co-authors caution prescribing clinicians to be aware of unusual but serious side effects associated with the treatment.

Short and long-term infliximab therapy for Crohn’s disease (CD) is generally well tolerated by patients, data from the Mayo Clinic in Rochester, Minnesota, USA, reveal. Reporting in the journal Gastroenterology, however, William Sandborn and co-authors caution prescribing clinicians to be aware of unusual but serious side effects associated with the treatment. (Source Gastroenterol 2004; 126 19-31)